Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerKathleen N. Moore, Paul DiSilvestro, Nicoletta Colombo et al.|New England Journal of Medicine|2018Cited by 2.9k
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 TrialPaul DiSilvestro, Kathleen N. Moore, Nicoletta Colombo et al.|Journal of Clinical Oncology|2020Cited by 122
Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian CancerKathleen N. Moore, Paul DiSilvestro, Nicoletta Colombo et al.|Obstetrical & Gynecological Survey|2019Cited by 53
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trialNicoletta Colombo, Paul DiSilvestro, Kathleen N. Moore et al.|Gynecologic Oncology|2021Cited by 37
Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trialAna Oaknin, Paul DiSilvestro, Kathleen N. Moore et al.|Annals of Oncology|2019Cited by 14